Zimmer Biomet Holdings, Inc. is Eubel Brady & Suttman Asset Management Inc.'s tenth largest holding.

Zimmer Biomet Holdings, Inc. specializes in orthopedic reconstructive goods and is responsible for their design, manufacture, and distribution.

‍

Also, there are products for the disciplines of sports medicine, biologics, trauma, extremities, spine, craniomaxillofacial, office-based technologies, dental implants, and associated surgical supplies.

‍

According to its most recent 13F filing with the SEC, Eubel Brady & Suttman Asset Management INC boosted its stake in Zimmer Biomet Holdings, Inc. shares by 4.3% during the third quarter of 2018.

‍

The medical equipment provider currently holds a total of 171,808 shares following the acquisition of an additional 7,160 shares during the quarter.

‍

Zimmer Biomet is the tenth largest position in the investment portfolio managed by Eubel Brady & Suttman Asset Management INC, accounting for around 3.2% of the total assets and ranking tenth overall.

‍

In its most recent filing with the SEC, Eubel Brady & Suttman Asset Management INC stated that it held 0.08% of Zimmer Biomet. The estimated worth of the company's shares at that time was $17,963,000.

‍

Many institutional investors have altered their stock holdings in recent months, either increasing or lowering their stakes in the stock. During the third quarter, Old North State Trust LLC acquired an additional 54,000 shares of Zimmer Biomet, increasing the total value of its stakes in this firm to roughly $54,000.

‍

Virtu Finance LLC boosted its investment in Zimmer Biomet during the second quarter by spending roughly $880,000.

‍

The total quantity of Zimmer Biomet shares owned by Nicolet Advisory Services LLC after the third quarter increased by 34.3% compared to the previous quarter. The most recent quarter saw Nicolet Advisory Services LLC acquire an extra 650 shares of the company's stock, bringing the total number of shares held by the firm to 2,544.

‍

This gives the company a current market capitalization of $272,000.

‍

During the third quarter, Assetmark INC boosted the amount of Zimmer Biomet shares it owned by 52.4%.

‍

Assetmark INC has 22,174 shares of the publicly listed firm, with a market capitalization of $2,318,000.

‍

This is due to the recent quarter's acquisition of an additional 7,621 shares by the corporation.

‍

Lastly, Bradley Foster & Sargent INC (CT) boosted its overall investment in Zimmer Biomet by 18.6% during the second quarter.

Bradley Foster & Sargent INC (CT) grew its holdings in the medical equipment firm by acquiring an additional 1,000 shares during the most recent fiscal quarter, bringing its total number of shares to 6,367 with a market value of $669,000.

‍

Institutional investors and hedge funds collectively hold 87.21% of the company's outstanding shares.

On Friday, the share price of NYSE: ZBH increased by $0.53, setting a new all-time high of $125.64. The business traded much less shares than its average daily volume of 1,653,260 shares, which was 107,910 shares.

‍

In the last fifty trading days, a share of Zimmer Biomet Holdings, INC stock has traded at a moving average price of $126.33. However, in the last two hundred trading days, this number has decreased to $116.99. The price has ranged between $100.39 and $135.05 throughout the past year.

‍

Currently, the company has a price-to-earnings ratio of 113.74, a beta of 1.02, and a price-to-earnings-to-growth ratio of 2.90.

It has a market capitalization of $26.37 billion based on its current market value. The debt-to-equity ratio now sits at 0.43, the quick ratio at 0.97, and the current ratio at 1.88.

‍

On February 3, the most recent quarterly earnings report for Zimmer Biomet, listed on the New York Stock Exchange under the symbol ZBH, was made accessible to the public.

‍

The medical equipment maker announced quarterly profits per share of $1.88, $0.05 better than the average estimate of analysts, who predicted earnings per share of $1.83.

‍

Analysts projected profits per share of $1.83.

‍

Zimmer Biomet's return on equity was 11.97%, while the company's net margin was 3.33 percent.

‍

In reality, the firm made 1.83 billion dollars in sales for the quarter, which is less than the 1.76 billion dollars in revenue projected for the time.

‍

During the same time period last year, the firm earned $1.95 per share. Comparing to the most recent quarter of the current year to the same quarter of the previous year, the company's revenue increased by 2.7%. Following the stock market, analysts predict that Zimmer Biomet Holdings INC will earn $7.04 per share during the current fiscal year.

‍

The company also declared a quarterly dividend, distributed on January 31. On Tuesday, December 27, dividends of $0.24 per share were given to the company's registered shareholders. These dividends were issued to shareholders whose ownership of the company's shares was documented. On Friday, December 23, stockholders had until midnight to make dividend payments to the firm without incurring a late payment charge.

‍

This corresponds to a quarterly dividend yield of 0.76% and an annual dividend payout of $0.96 for the investor.

‍

Currently, 87.27% of Zimmer Biomet's income is given to stockholders as dividends.

‍

In a report issued on January 5, Raymond James raised the rating for Zimmer Biomet from "market perform" to "outperform." Raymond James also assigned a $140.00 price objective on the company's shares.

‍

Loop Capital said in a research note dated February 6 that it has lifted its price target for Zimmer Biomet from $125.00 to $140.00.

The earlier price aim was $125.00. Robert W.

‍

In a February 6 research report made accessible to the public, Baird raised their price target for Zimmer Biomet from $133.00 to $145.00. Evercore ISI published a research note on Tuesday, January 3, in which it downgraded Zimmer Biomet from a "outperform" rating to an "inline" rating and set a $130.00 price target on the company.

‍

In a research note dated November 23, Wells Fargo & Company boosted their price target for Zimmer Biomet from $116.00 to $120.00 and upgraded the company from "underweight" to "equal weight."

‍

Three research specialists suggested selling the stock, six analysts suggested maintaining the stock, and six suggested purchasing the stock.

‍

According to information provided by Trade Algo, the stock has been assigned a current rating of "Hold," and analysts' average price target is $132.18.

‍